The molecule contained in breast milk helps counteract Alzheimer’s Diseases progression

Alzheimer‘s usually has a sneaky start: you start forgetting certain things and end up not even recognizing the closest family members. Alzheimer’s disease, which affects memory and cognitive functions, today affects about 5% of people over 60 years of age, and in Italy, there are an estimated 500,000 cases, numbers that identify this disease as one of the most widespread in our civilization.

The researchers of Ce.Ri.Fo.S, the Scientific Research and Education Center on Rare Diseases in Endocrinology and Immunology, who have been conducting specialized studies in this field for years, have no doubt: today Alzheimer‘s disease can be tackled since its onset and successfully fought.

Alzheimer‘s is considered by the team of Ce.Ri.Fo.Ss within a dysmetabolism, mainly due to the lack of glucose supply to the brain, caused by a deficit in the functioning of the insulin receptor.

In order to fully understand this mechanism, we must start from the fact that the brain needs about 100-150 g of glucose per day for its functioning, but the blood can only store 5 g of it, so a continuous supply is needed. The undisputed protagonist in this process is the insulin receptor, which plays a fundamental role: when it recognizes the presence of insulin, it sends a signal inside the cell that allows the opening of a gap in the cell membrane at the exact moment when it needs it.

What they share Diabetes and Alzheimer‘s disease is the defect of the insulin receptor, which, while in Alzheimer’s disease concerns the insulin receptor of the central nervous system, in diabetes it is borne by the ß cells of the pancreas. This link justifies the scientific evidence that people with type I or II diabetes suffer more frequently from Alzheimer‘s disease than those who do not. With the recognition of the importance of sugar metabolism, the identification of Alzheimer‘s disease as type III diabetes is spreading. Because of the insulin receptor deficit, amyloid plaques are formed inside the brain tissue that cause the neurons to lose efficiency until they die. This process of degradation is quite slow; it begins many years before the onset of symptoms and gradually spreads until it reaches the hippocampus, the structure responsible for the memorization process. In essence, the more neurons die, the more the affected areas of the brain begin to shrink and the brain begins to “hunger for sugar”. It is at this point that the first signs of dementia become visible.

The solution, at least in part, is integration with galactose, a sugar that, unlike glucose, requires neither insulin nor its receptor to be absorbed by cells, which, as we have seen, does not work properly in patients affected by the disease. Galactose, in fact, to get inside the cell uses a different carrier, called GLUT 3, and for this reason it is the only nutritional element that can stop the hunger for sugar in the brain. If we consider, moreover, that galactose is the sugar of mother’s milk, therefore closely linked to growth and cellular structuring, we can easily guess which primordial and essential element we are approaching: for the regeneration of the nervous system, damaged by degenerative pathologies such as Alzheimer’s, we use the same principle that is used by the child to repair, generate or regenerate the neurological system.

Galactose is not the treatment of choice for Alzheimer‘s disease, but certainly this sugar can greatly improve the symptoms, as demonstrated in many studies carried out by Ce.Ri.Fo.S.

Our Research Centre has observed improvements in blood sugar levels in Alzheimer‘s patients with type ll diabetes. In one of the most recent studies, patients with MCI (Mild Cognitive Impairment) were given galactose daily for six months. At the beginning, in the middle and at the end of the intervention phase, cognitive performance was tested with different types of tests, during which significant improvements were found in specific areas of brain function. The results of this pilot study suggest that the administration of galactose improves the energy supply to brain cells to such an extent that they do not decay with age.

Another study aimed at diabetes II patients with bi-weekly administration of galactose 10% intravenously and oral intake of 10 g. daily showed a significant improvement in blood glucose values, bringing them back to the threshold within 3 months.

The right approach to the pathology according to Cerebro®

An essential fact is the stage of the disease.

“Intervening at the first symptoms greatly improves the prognosis” comments Dr. Samorindo Peci, scientific director of Ce.Ri.Fo.S, who has been carrying out research on the pathologies listed above for years.

The protocol is composed of four phases, which can be customized according to individual responses.

For us, the therapeutic novelties, completely biological, used for Alzheimer‘s, in addition to galactose to be administered in mini IV for attack therapy and in os solution in maintenance posology, are the combined amino acids, which are used to activate cell respiration and cell extracts for tissue regeneration. And thanks to the contribution of international collaborations on the production of these combined molecules, we are having excellent results.

It is also important to take the nutritional approach into account in the approach to the disease. Starting from the idea that every pathology, including Alzheimer‘s disease, requires a clinical evaluation in its own right, we believe it is useful in this case to address a predominantly protein-based nutrition, giving more emphasis to vegetable proteins than animal proteins without introducing carbohydrates.  This type of nutrition represents a medical act, so many functional and physiological factors that need to be monitored over time must be taken into account.

Cerebro®, with the collaboration of Ce.Ri.Fo.S and international partners, is included in the Galactose production line to support patients in the initial and intermediate stages of the disease.

[Fonte: Medicina di Frontiera anno I, Nr. 1]

By Federica Peci

Psychologist and Scientific Journalist

In cooperation with Cerebro® Staff

Cerebro ® , an Innovativation and High-Tech Neuroscience Start-Up, which helps patients in medical practices and associated clinics through different methods and approaches to improve the perception and quality of life of each individual.